National Bank of Canada
BTAI icon

National Bank of Canada’s BioXcel Therapeutics BTAI Stock Holding History

National Bank of Canada’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$11 – 2883
2025
Q2 		$11 Sell
6
-21
-78% -$35 ﹤0.01% 2938
2025
Q1 		$54 Sell
27
-37
-58% -$138 ﹤0.01% 2747
2024
Q4 		$381 Sell
64
-84
-57% -$702 ﹤0.01% 2733
2024
Q3 		$1.45K Sell
148
-15
-9% -$202 ﹤0.01% 2393
2024
Q2 		$3.06K Buy
163
+24
+17% +$803 ﹤0.01% 2359
2024
Q1 		$4.63K Buy
139
+22
+19% +$1.05K ﹤0.01% 2321
2023
Q4 		$5.49K Buy
117
+44
+60% +$2.45K ﹤0.01% 2285
2023
Q3 		$2.81K Buy
73
+38
+109% +$3.84K ﹤0.01% 2465
2023
Q2 		$3.77K Hold
35
– – ﹤0.01% 2394
2023
Q1 		$10.6K Sell
35
-8
-19% -$3.42K ﹤0.01% 2125
2022
Q4 		$14.6K Hold
43
– – ﹤0.01% 2084
2022
Q3 		$8K Sell
43
-3
-7% -$697 ﹤0.01% 2234
2022
Q2 		$10K Hold
46
– – ﹤0.01% 2259
2022
Q1 		$15K Sell
46
-3
-6% -$870 ﹤0.01% 2255
2021
Q4 		$16K Buy
+49
New +$21K ﹤0.01% 2215

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

National Bank of Canada's BTAI Position: Q3 2025 in Review

National Bank of Canada sold out of BioXcel Therapeutics (BTAI) in Q3 2025, closing a stake of 6 shares — an estimated $11 sold.

National Bank of Canada first reported a position in BTAI in Q4 2021 and held it in 15 quarters. The position peaked at $16K in Q4 2021. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

  • National Bank of Canada reported no remaining BioXcel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 6 BioXcel Therapeutics shares in Q3 2025, an estimated $11.
  • National Bank of Canada first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 15 quarters.
  • National Bank of Canada's BioXcel Therapeutics position peaked at $16K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.